Report : North America Quantitative Structure-Activity Relationship Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Application (Drug Discovery, Molecular Modelling, Chemical Screening, Regulatory and Decision-Making, and Others); Industry (Pharmaceuticals, Cosmetics, Environmental, and Food & Beverage)

Drug Discovery Segment has the Largest Share of Application in the North America Quantitative Structure-Activity Relationship Market during 2020–2027

According to a new market research study on “North America Quantitative Structure-Activity Relationship Market to 2027 – COVID-19 Impact and Regional Analysis and Forecast by Application, and Industry,” is expected to reach US$ 786.6 million by 2027 from US$ 590.2 million in 2020. The market is estimated to grow at a CAGR of 4.2% from 2020 to 2027. The report provides trends prevailing in the North America quantitative structure-activity relationship market along with the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the increasing adoption of modelling tools in drug discovery and increasing economic burden of drug discovery. However, the market is expected experiencing slow growth during the forecast period owing to the less adoption in emerging countries.

The first of the National Institute of Allergy and Infectious Diseases’ (NIAID) Covid-19 research priorities is to improve understanding of the disease and the novel coronavirus that causes it, SARS-CoV-2. This helps with understanding the transmission of the disease, including determining whether it is likely to be seasonally circulating, as well as why Covid-19 so dramatically affects some individuals, while others remain asymptomatic. But better knowledge about the virus and the disease can also support the identification of new drug targets or which existing drugs could help tackle this viral disease. Drugs are essential to stopping more suffering at the hands of Covid-19; at the time of writing, more than 461,000 people have tragically died from the disease in the US. The most critical method for anti-SARS-CoV-2 drug discovery includes the de novo development of new, specific drugs based upon the genomic and biophysical understanding of this virus. For instance, the determination of key SARS-CoV-2 targets may bring about the production of siRNA molecules or inhibitors against specific viral enzymes correlated with viral replication. The intensive vaccines and potential immunity boosting drug development procedures and ramping up of food testing services, which is expected to create a positive impact on the growth of quantitative structure-activity relationship (QSAR) market in the North American region.

The market for quantitative structure-activity relationship market is segmented into application and industry. The quantitative structure-activity relationship market based on application is segmented into drug discovery, molecular modelling, chemical screening, regulatory and decision-making, and other applications. In 2019, the drug discovery accounted for the largest share and is expected to grow faster during the forecast period as it often involves the use of QSAR to identify chemical structures that could have good inhibitory effects on specific targets and have low toxicity (non-specific activity). Of special interest is the prediction of partition coefficient log P, which is an important measure used in identifying "drug likeness" according to Lipinski's Rule of Five. Moreover, companies have collaborated with pharmaceutical companies to speed up the drug discovery and development.

ProtoQSAR SL, Intertek Group Plc, Laboratory Corporation of America Holdings, LATHAM BIOPHARM GROUP, NSF INTERNATIONAL., and Creative Biolabs are among the leading companies in the North America quantitative structure-activity relationship market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in November 2020, Novartis has received a global license to Mesoblast’s quantitative structure-activity relationship (QSAR) Remestemcel-L in the treatment of COVID-19. The deal lands Mesoblast $50 million upfront and a partner's support that could help address critical quality attribute concerns raised by the FDA.

The market for quantitative structure-activity relationship market is segmented into application and industry. Based on application, the quantitative structure-activity relationship market is segmented into drug discovery, molecular modelling, chemical screening, regulatory and decision-making, and other applications. Based on end user, the quantitative structure-activity relationship market is segmented into pharmaceuticals, cosmetics, environmental, and food & beverage. Geographically, the quantitative structure-activity relationship market is segmented into North America (US, Canada, Mexico).

Contact Us
Contact Person: Sameer Joshi 
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com 

Download Free PDF Brochure